Prevacidlansoprazole

According to the FDA label: Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of H.

171,879 adverse event reports submitted to the FDA (1997–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Prevacid in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Prevacid adverse event reports by reporter sex
SexReports
Female83,424
Male59,894
Unknown307

By Age Group

View age group data as a table
Prevacid adverse event reports by reporter age group
Age groupReports
0-174,999
18-345,521
35-4914,853
50-6429,823
65-7425,833
75+27,568

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Prevacid. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Prevacid adverse event reports by reported outcome
OutcomeReports
Other Serious106,155
Hospitalization63,427
Non-Serious20,716
Death19,456
Life-Threatening11,961
Disability9,562

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Prevacid. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Prevacid adverse event reports by year
YearReports
19971
20011
20034
20043,205
20053,611
20063,398
20072,907
20083,190
20093,648
20104,397
20114,959
20125,927
20134,692
20145,061
20157,373
20168,060
20177,250
201824,720
201924,506
202011,112
20219,305
20227,977
20238,200
20248,690
20257,879
2026 (partial)1,806

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Prevacid

In FDA adverse event reports that mention Prevacid, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026